NeuroOne

ADVANCING NEUROSCIENCE

Corporate Presentation

Nasdaq: NMTC

June 2026

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects NeuroOne's current views about future events. In some cases, you can identify forward–looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "upcoming," "target," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue" and "ongoing," or the negative of these terms, or other comparable terminology. Forward–looking statements may include statements regarding additional potential strategic partnerships, the potential for revenue related to trigeminal nerve ablation, the expectation to commercialize our drug delivery system for animals or approved IDE studies by end of calendar Q2 2026, the potential for international commercialization, the expectation of product revenue increasing to at least $10.5 million in fiscal year 2026, the timing and extent of product launch and commercialization of our technology, growth in revenue and profitability, clinical and pre-clinical testing, business strategy, market size, potential growth opportunities, future operations, future efficiencies, and other financial and operating information. Our actual future results may be materially different from what we expect due to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; risks that our sEEG electrodes may not be ready for commercialization in a timely manner or at all, whether due to supply chain disruptions or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company's capital requirements to achieve its business objectives and ability to raise additional funds; the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks related to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this presentation and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market share and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

Caution: Federal law restricts this device to sale by or on the order of a physician.

Our Vision

We are Driven to Transform the Lives of Patients Battling **Neurological Disease** and **Chronic Pain** — Conditions That Have Long Deserved Better Solutions

Clara, 18 years old

10

seizures nightly

to seizure free for 1 year*

Treated with the NeuroOne RF Ablation System

* Disclaimer: This recounts a patient's experience and may not be representative of all patient outcomes. After one year, patient developed new seizures in a new location and was subsequently treated with laser ablation

Investment Highlights

Validated Platform Technology

- 4 FDA 510(k) Clearances
- Partnership with ZIMMER BIOMET

Underpenetrated Core Markets

- Underpenetrated epilepsy and trigeminal neuralgia ablation opportunity
- $200m+ market with significant growth potential

$3b+ Mkt. Expansion Opportunity

- Basivertibral Nerve Ablation, Spinal Cord Stimulation, and Drug Delivery
- Leverages existing clearances

Enabled by Proprietary Flexible Thin Film Electrode Technology

Driving revenue growth, improving financial profile, and strategic collaboration potential

Competitive Moat Around Every Product We Build

Proprietary Flexible Thin Film Platform Technology

Combined Diagnostic and Therapeutic Capabilities

- Only FDA-Cleared device that uses the same sEEG electrode for both diagnostic and therapeutic applications
- Designed to reduce hospitalizations and potentially additional procedures

Ultra-Thin / Flexible

- Significantly less invasive
- Enables percutaneous (needle) placement vs. surgical

Multi-Contact Targeting

- Ablate multiple locations without repositioning (speed/comfort)
- Reduces placement precision burden on the surgeon

Biocompatible

- Supports extended implant duration
- Potential repeat drug delivery without additional procedures



13
Issued/Pending US Patents

4
Issued/Pending OUS Patents

Proprietary manufacturing trade secrets

Our Platform Addresses Multi-billion $ and Growing Markets[1]

Actual Market

Potential Market Size

1. Company data on file
2. Brain EEG and RF ablation for epilepsy and RF for trigeminal neuralgia

Mayo Clinic Partnership

- Mayo Clinic performed initial testing of technology in pre-clinical models and clinical research
- Mayo Clinic leading neurologist, Dr. Worrell, chairs the NeuroOne Scientific Advisory Board
- First commercial human use of Evo® Cortical Electrodes performed at Mayo Clinic in November 2020
- Currently using NeuroOne drug delivery system in pre-clinical animal studies

Mayo Clinic Advisory Board Representation

Greg Worrell MD, PhD, Chairman of the Scientific Advisory Board

World renowned neurologist at Mayo Clinic. Recognized by the American Epilepsy Society (AES), the American Academy of Neurology (AAN), the American Neurological Association (ANA), and the Citizens United in Research for Epilepsy (CURE) Foundation for his contributions to the field of epilepsy research. Dr. Worrell is a frequent keynote speaker at neurology conferences and has published 90 papers.

Jamie Van Gompel, MD

Neurosurgeon practicing at Mayo Clinic, specializing in epilepsy surgery utilizing minimally invasive techniques. Since 2008, Dr. Van Gompel has authored or co-authored 87 papers on clinical outcome projects centered on neurological conditions. Dr. Van Gompel works collaboratively with colleagues from Mayo Clinic's Epilepsy and Neurophysiology lab, engaging in clinical work relative to brain stimulation as a viable restorative therapy for epilepsy over current treatment methodologies.

Zimmer Biomet Partnership

- Zimmer is a worldwide leader in robotic technology used in minimally invasive neurosurgeries
- NeuroOne sEEG electrodes are complementary to Zimmer's ROSA ONE® robotic neurosurgery platform
- Partnership initiated in 2020: $8.5 million total licensing revenue paid to NeuroOne to date

Expanded partnership to include distribution rights for NeuroOne's OneRF® Ablation System in the brain

- $3 million licensing fee
- Expanding in US and preparing to commercialize in select OUS countries
- Expected to boost NeuroOne revenue growth and profitability

Technology Platform

Product Portfolio

	Product		Use Case	Partner	FDA Cleared
Neurology	Evo® Cortical Electrodes		Recording brain activity placed on surface of brain	ZIMMER BIOMET	510(k) ✓
	Evo® sEEG Electrodes		Recording brain activity Placed deeper Into the brain	ZIMMER BIOMET	510(k) ✓
	OneRF® Ablation System for Brain		Ablating brain tissue using sEEGs with dedicated RF console	ZIMMER BIOMET	510(k) ✓
	Drug Delivery System		Designed for recording brain activity and therapeutic agent delivery		
Chronic Pain	OneRF® Trigeminal Nerve Ablation System for Facial Pain		Ablating trigeminal nerve tissue using TNRF probe and dedicated RF console		510(k) ✓
	Basivertebral Nerve Ablation (BVNA)		Designed for RF ablation of nerve in the vertebral body to relieve back pain		
	Spinal Cord Stimulation (SCS)		Designed for chronic recording & stimulation – Placed percutaneously vs. surgical implant		

NeuroOne
NASDAQ: NMTC

In development

Thin-Film Evo® sEEG & Cortical Electrodes

Summary

- Increased signal clarity /reduced noise design
- Cortical device thinner & lighter than competitive devices
- sEEG - Better tactile feedback during brain tissue insertion
- Both product lines are distributed by Zimmer Biomet

Applications

- Epilepsy surgery for brain mapping
- Brain tumor mapping

Distribution Partner

ZIMMER BIOMET

Evo® Cortical



Evo® sEEG

OneRF® Ablation System for Brain

Summary

- One procedure for diagnostic and therapeutic expected to save time, money and to improve patient outcomes
- Temperature-guided ablation provides additional safety measure
- Designed to reduce number of procedures and hospitalizations
- Uses well established RF energy to ablate tissue
- Only device cleared by FDA for both diagnostic and RF ablation procedure using the same device

Distribution Partner

ZIMMER BIOMET

Evo® sEEG

Single-Use RF Procedure

Capital Equipment

OneRF® Trigeminal Nerve Ablation System for Facial Pain (Trigeminal Neuralgia-TN)

Received 510(k) clearance from FDA in August 2025

Summary

- Treatment with proven clinical efficacy with established reimbursement
- OneRF introduces the first multi-contact probe for TN ablation
  - This enables stimulation and ablation in same cannula/probe insertion
  - May lead to fewer anesthesia cycles, more efficient and comfortable procedure for the patient
- Works with NeuroOne's modern RF Generator
- Evaluating strategic partnership opportunity
- Successfully completed our first sixteen cases, with all patients reportedly pain free*

Single Use: TNRF Probe & Cannula



Single Use: RF Accessories



Capital Equipment

NeuroOne
NASDAQ: NMTC

* Disclaimer: This recounts several patients' experiences and may not be representative of all patient outcomes.

BVNA – Leveraging Existing NeuroOne Technologies

Key Highlights of the System

Multi-contact probe

- More contacts = more placement flexibility
- Temperature controlled ablation
- Gen 2 – Develop regulatory strategy to pursue drug delivery

Modern RF Generator

- Graphical display, touchscreen interface
- Multiple modalities of treatment possible

Speed to market / Proven System

- Generator and RF probe 510(k) cleared for Brain and Trigeminal Nerve Ablation
- Currently used in brain and TN/Facial pain ablation
- Impressive efficacy and safety profile for brain ablations



Next-Gen Multi-Contact Probe

(FDA cleared for brain and trigeminal nerve ablation)

Modern RF Generator

(510k cleared for ablation of nervous tissue)

$1B+

Addressable Market

sEEG-Based Drug Delivery System

Designed to leverage our sEEG platform enabling drug delivery + brain activity recording

Pre-Drug Delivery

Record Brain Activity with sEEG Electrode(s)

Drug Delivery

Via Catheter Inserted Through sEEG Electrode(s)

Post-Drug Delivery

Record Brain Activity with sEEG Electrode(s)



Drug Delivery Time Lapse

Illustration in Gel



Summary

- Does not require MRI for placement / drug delivery;
- Supports multiple trajectories and simultaneous catheter drug infusions, with the potential to significantly reduce operating room time and improve procedural efficiency.;
- Ability to record brain activity pre-, during, and post-drug delivery; utilizes proven sEEG technology
- Leverages small diameter and design of our current sEEG products
- Open platform - does not require investment in proprietary software, infusion or navigation systems
- Status: Company expects to commercialize for animal studies and approved FDA IDE/IND human studies

$1B+

Addressable Market

Spinal Cord Percutaneous Paddle Lead

Summary

- Percutaneously placed paddle electrodes through a 14-gauge needle for spinal cord stimulation
- Able to stimulate broadly and precisely target tissue; ability to customize different stimulation patterns
- Advisory Board of leading pain specialists & neurosurgeons
- Company in diligence discussions with potential strategic partners to accelerate time to commercialization

Perc-Paddle Lead (Electrode)





Implantation Kit

Current Solutions

Most procedures use small percutaneous cylindrical electrodes that have limited stimulation coverage and high battery usage

$3B+
Global Market

NeuroOne's Solution

A percutaneously implantable paddle lead with greater stimulation coverage and expected reduced battery usage

Management Team

Dave Rosa
President & Chief Executive Officer

Ron McClurg
Chief Financial Officer

David Wambeke
Chief Business Officer

Steve Mertens
Chief Technology Officer

Chris Volker, CFA
Chief Operating Officer[1]

Emily Johns
Chief Administrative Officer & General Counsel

Mark Christianson
Co-Founder, Market Development Director

Hijaz Haris
Vice-President of Marketing

Camilo Diaz Botia
Vice President of Engineering

* 1) As part of the Chief Financial Officer Succession Plan announced on April 30, 2026, Chris Volker will assume the role of Chief Financial Officer, on a permanent basis, on June 30, 2026.

Financial Overview

Highlights & Financial Catalysts

- Debt free balance sheet
- Accounts receivable of $1.9M
- 1H FY2026 Financials:
  - 1H 2026 product revenue of $4.8M
  - 1H 2026 product gross margin of 54.0%
- FY26 product revenue expected to increase to at least $10.5 million representing at least 15% annual growth
- Potential new partnerships focused on pain management and drug delivery

Capital Position

	($ in millions)
Cash (as of 3/31/26)	$2.8
Accounts Receivable	$1.9
Debt	$0.0
1H FY 2026 Product Revenue	$4.8

Analyst Coverage

Ladenburg Thalmann	Jeffrey Cohen
Maxim Group	Anthony Vendetti
JonesTrading	Justin Walsh

Key Takeaways

Validated platform technology

Underpenetrated $200+ million neurology market with significant growth opportunity

$3+ billion market expansion opportunity

Driving revenue growth, improving financial profile, and strategic collaboration potential

Thank You

Investor Relations:

Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
NMTC@mzgroup.us